Citation: Carr BJ, Mihara K, Ramachandran R, et al. Myopia-inhibiting concentrations of muscarinic receptor antagonists block activation of alpha 2A -adrenoceptors in vitro. Invest Ophthalmol Vis Sci. 2018;59:2778-2791. https://doi.org/10.1167 PURPOSE. Myopia is a refractive disorder that degrades vision. It can be treated with atropine, a muscarinic acetylcholine receptor (mAChR) antagonist, but the mechanism is unknown. Atropine may block a-adrenoceptors at concentrations ‡0.1 mM, and another potent myopiainhibiting ligand, mamba toxin-3 (MT3), binds equally well to human mAChR M 4 and a 1A -and a 2A -adrenoceptors. We hypothesized that mAChR antagonists could inhibit myopia via a 2Aadrenoceptors, rather than mAChR M 4 .
M yopia (near-or short-sightedness) is a common eye condition that increases the risk of ocular pathology as it progresses. 1, 2 As its prevalence continues to rise, 3 so does the need for an effective therapy. Topical atropine is effective against myopia in children 4 ; however, treatment requires daily application, and the dosage most commonly prescribed for many years (1%) may induce allergic reactions, as well as muscarinic acetylcholine receptor (mAChR) M 3 -mediated side effects-mydriasis, photophobia, cycloplegia-and possibly early presbyopia. 4, 5 Atropine administered topically at concentrations of 1% loses effectiveness over a period of 1 to 2 years; and upon cessation, ''rebound'' may occur, wherein myopia returns at a faster rate than in untreated eyes 6, 7 -possibly because of the desensitization of target receptors in response to a high concentration of anticholinergic drug. Recent studies have supported the use of 0.01% atropine to treat childhood myopia. 7, 8 This comparatively lower dose of atropine appears to retain its effectiveness for inhibiting myopia, and results in a reduced severity of side effects such as allergies, loss of accommodation, and rebound. Some of those treated with 0.01% atropine still complain of muscarinic receptor (mAChR) blockade-induced complications, including photophobia and blurred vision; however, those symptoms are not severe enough to prompt a discontinuation of treatment. Therefore, 0.01% atropine is currently the most favored concentration prescribed by clinicians both in Southeast Asia and North America. [9] [10] [11] [12] Atropine is a potent nonselective mAChR antagonist. Thus, it has been widely assumed to inhibit myopia via blockade of mAChRs. Another potent mAChR antagonist, mamba toxin-3 (MT3), is strongly selective for mAChR M 4 over other mAChR subtypes in mammals, 13 and inhibits form-deprivation myopia (FDM) in the chick at far lower concentrations than those required for atropine (17.5-70 pmol versus 20-2000 nmol per injection, respectively). [14] [15] [16] Therefore, given the ability of MT3 to block myopia development in the chick model, it has been suggested that the mAChR M 4 receptor subtype is the target for myopia-controlling action of both atropine and MT3. 14, 17 It is important to point out, however, that a direct mechanistic link between mAChR systems in the eye and the mAChR antagonist properties of atropine or MT3 for inhibition of myopia has never been demonstrated.
Moreover, some evidence suggests that the ability of atropine to inhibit myopia development may not involve mAChRs at all. 18 For example, most mAChR antagonists, even very potent ones such as 3-quinuclidinyl benzilate (QNB) or dicyclomine, do not inhibit myopia in chicks, and those muscarinic antagonists that do so inhibit myopia require concentrations that can be orders of magnitude above their inhibition constants for blocking mAChRs (Table 1) . 16, 19 Furthermore, ablating ‡90% of choline acetyltransferase (ChAT)-containing amacrine cells-the only known source of retinal acetylcholine (ACh; the natural agonist at mAChRs)-in the chick has no effect on the eyes' ability to achieve emmetropia, nor does elimination of retinal ChAT impair myopia inhibition by atropine. 20 Treatment with myopiainhibiting concentrations of atropine in chick retina-RPEchoroid-sclera preparations causes a massive, nonspecific release of retinal neurotransmitters (including dopamine), and induces spreading depression that affects the entire retina, not just mAChR-related circuits. 21 Finally, significant myopiarelated changes in eye size in the tree shrew and chick do not result in significant changes in mRNA or protein expression of any mAChR subtype in the retina, 22, 23 nor does myopiainduced axial elongation result in changes in the concentration of retinal ACh, or its metabolite choline. 24 Results such as these have led to arguments that favor a nonretinal mechanism of atropine-mediated myopia inhibition, with mAChR binding in the choroid or sclera suggested as the most likely alternative. One way to determine whether the molecular targets of antimyopia therapy-that are modified directly by treatment with mAChR antagonists-are located in these tissues, is to look for changes in receptor density upon induction of experimental myopia and during atropine treatment. There is no change, however, in mAChR mRNA expression in either the choroid or sclera, upon induction of experimental myopia in intact eyes of tree shrew and chick. 22, 23 A second method to determine whether the choroid or sclera is directly responsible for atropine-mediated myopia inhibition is to examine the responses to atropine in these tissues specifically, in in vitro preparations of eyecups lacking retina. In such preparations, the action of atropine to inhibit extracellular matrix production and sulfate incorporation into the glycosaminoglycans of chick scleral cartilage 25 and the inhibition of carbacholinduced mouse scleral fibroblast proliferation 26 were observed only at high concentrations of atropine (0.5-100 lM in the medium), which are 500-to 10,000-fold higher than those that block mAChRs (K i ¼ 1-10 nM; Table 1 ). Finally, while pirenzepine treatment has been shown to result in changes in choroidal thickness when applied to in vitro preparations of chick eyecups comprising the RPE-choroid-sclera, it did so only at high concentration (5 mM); other mAChR-targeted antagonists, such as oxyphenonium (1 mM) and dicyclomine (0.6 mM), had no effect on the choroid in these preparations. 27 Unfortunately, the effect of atropine on choroidal thickness in chick eyecups lacking retina was not tested.
Of particular interest in the above examples is the requirement of high concentrations of atropine and other mAChR antagonists for myopia-inhibiting effects, relative to the subnanomolar affinities (K i ) of many of these antagonists for the M 4 mAChR (Table 1) . Indeed, even if a drug binds selectively to its preferred receptors with high affinity (e.g., K i 1 nM), it is expected that at concentrations two to three orders of magnitude higher it will bind to, and affect the activity of, other (''off-target'') receptors. 21 Thus, atropine, while receptor-selective at nanomolar concentrations, would very likely have off-target effects at other receptors at the micro-to millimolar concentrations used to mitigate myopia. Additionally, while it is true that MT3 can inhibit myopia at much lower concentrations than atropine, 14, 15 this result cannot be interpreted to mean that it does so through M 4 or any other mAChR on this basis alone. Although MT3 is selective for the M 4 receptor over other mAChRs, 13, 28 it has a comparably high inhibitory potency (IC 50 ¼ 1-10 nM) at human a 1A -, a 1D -, and a 2A -adrenergic receptors; moderate inhibitory potency (IC 50 ¼ 25-50 nM) at a 1B -and a 2Cadrenergic receptors; and low inhibitory potency (IC 50 ¼ 200 nM) at the mAChR M 1 receptor. 29, 13 There are also data to indicate that at high concentrations (1-100 lM) atropine can also have antagonist activity at a-adrenoceptors, 30, 31 although the specific adrenoceptor subtypes to which it may bind remain unknown.
Chicks are a popular animal model for myopia drug studies. They have high-quality vision, active accommodation and emmetropization, and large eyes for easy intravitreal drug delivery. Diffusers [32] [33] [34] and negative lenses 35, 36 induce large changes in axial length and refractive error (À5 to À15 diopter [D]) in a matter of days, and results from chick experiments can usually be replicated in mammals and nonhuman primates. 37 Interpretations of results, using mAChR antagonists to prevent FDM in the chick, have generally presumed that these ligands work the same way at avian receptors as they do at human or other mammalian receptors. That said, the chick retinal structure and G-protein receptor sequences differ significantly from those of mammals. Chickens lack an orthologue for the mammalian mAChR M 1 . Instead, chicken M 2 (cM 2 ), the orthologue for the mammalian M 2 receptor, has some pharmacologic properties of both mammalian M 1 and M 2 receptors, such as relatively high affinity for pirenzepine. 38 Thus, in the chick, one can conclude that MT3 will target the M 4 mAChR and not other mAChR subtypes. Furthermore, there are examples of substantial differences in ligand behavior between species, even for mammals, whereby even minor sequence differences can cause receptor-selective ligands to interact differently, with the same G-protein-coupled receptor (GPCR) orthologue. 39, 40 We therefore considered it likely that MT3, which is highly selective for the mammalian M 4 receptor, might have a significantly altered ability to bind to the chick M 4 receptor.
Given the likelihood that the concentrations of atropine used for treating myopia in humans and chicks can act at receptors other than mAChR M 4 , we focused on the molecular pharmacology of the chick cM 4 and human M 4 receptors, and the interactions of these receptors with the mAChR-targeted agents that have been used to evaluate myopia development in the chick model. Furthermore, since both MT3 and atropine can potentially interact with a-adrenoceptors, we also explored the interactions of FDM-mitigating agents with the human a 2A -adrenergic receptor ADRA2A (hADRA2A) subtype. To test the hypothesis that non-mAChR mechanisms can mediate the inhibition of myopia development by mAChR antagonists in the chick FDM model, we evaluated (1) whether mAChR antagonists have similar relative inhibitory potencies at chick cM 4 compared to human M 4 , and (2) whether mAChR antagonists can bind to, and inhibit signaling by, hADRA2A. We chose to investigate the binding of mAChR antagonists to a 2Aadrenoceptors because MT3 has a high affinity for these adrenergic receptors, because this adrenoceptor is the most common a-adrenoceptor subtype in the central nervous system, 41 and because some a 2 -adrenoceptor agonists have been reported to inhibit FDM in the chick (Carr BJ, Stell WK. IOVS 2016;57:ARVO E-Abstract 4738) and guinea pig. 42 
METHODS AND MATERIALS Experimental Strategy
Our strategy to explore the interactions of the FDM-related antagonists with either mAChR M 4 /cM 4 or hADRA2A was to express the recombinant receptors in a mammalian Lenti-X HEK 293T cell line, in which the only endogenously expressed mAChR (M 3 ) was eliminated by a CRISPR/Cas9-mediated genomic editing approach (CRISPR-M 3 cells: CR-M 3 ). The HEK cell line is well recognized for its ability to couple the signaling of GPCRs from multiple species efficiently to multiple effectors, including G s , G i , G q , and G 12/13 . In this system, the abundance of expressed muscarinic and adrenergic receptors enables coupling to G s , with a resulting increase in synthesis of cyclic AMP (cAMP). 43, 44 In turn, the cAMP drives a cAMP response element (CRE)-luciferase reporter construct, such that increased luciferase activity serves as an index of activation of the transfected muscarinic and adrenergic receptors. Carbachol was used to activate the chick and human mAChRs, and clonidine was used as the agonist to activate hADRA2A. The ability of increasing concentrations of antagonists to inhibit the cholinergic and adrenergic responses was used as an index of their relative potencies for blocking the expressed receptors. The relative inhibition constants of the myopia-inhibiting compounds, for blocking either the muscarinic or a 2A -adrenergic receptors, were compared directly with the relative ability of the compounds to mitigate myopia in the chick FDM model.
DNA and Expression Vectors
All receptor clones were expressed in a pcDNA 3.1(þ) vector (Invitrogen, ThermoFisher Scientific, Waltham, MA, USA). The cM 4 genomic clone was obtained as previously described, 18 and the M 4 (MAR0400000) and hADRA2A (AR0A2A0000) receptor clones were purchased from the cDNA Resource Center (Bloomsburg University Foundation, Bloomsburg, PA, USA). The cAMP response element luciferase vector (CRE-Luc; pGL4.29[luc2P/CRE/Hygro]) and the constitutively active Renilla luciferase control vector (RLuc; pRL-RK) were purchased from Promega (Madison, WI, USA).
CRISPR/Cas9 Knockdown of mAChR M 3
CRISPR knockout of mAChR M 3 in Lenti-X HEK 293T cells (LX293T; Clontech, Mountain View, CA, USA) was performed to ensure that mAChR ligand-mediated effects on cAMP were the result of activity at transfected, and not endogenous, receptors. 45, 46 Stable CRISPR M 3 -knockout LX293T cells are referred to as CR-M 3 cells. Cell culture medium, serum, transfection materials, culture flasks, and multiwell plates were purchased from ThermoFisher Scientific unless specified otherwise. The knockout design and procedures used to derive the CR-M 3 cells from the wild-type LX293T cells, using the GeCKO CRISPR protocol (available in the public domain, https://www.addgene. org/crispr/libraries/geckov2/), were as described by Sanjana et al. 47 and Shalem et al. 48 Three sets of genome-specific single guide RNA sequences to mAChR M 3 (F to R) were chosen from the GeCKOv2 Human Library, and both strands of oligonucleotides were synthesized for each target sequence (F A : CACCGgtc acaagcgcgcacccgagc; R A : AAACgctcgggtgcgcgcttgtgacC; F B : CACCGgcggtaccaccgatgaccctc; R B : AAACgagggtcatcggtgg taccgcC; F C : CACCGgcgctttcttaacgggcatcc; R C : AAACggatgcccgt taagaaagcgcC); the lowercase sequences are target sequences of the M 3 genomic locus, and the uppercase sequences are flanking sequences for cloning. Both strands of the oligonucleotides were annealed and inserted in BsmBl restriction enzyme sites under a U6 promoter in a CRISPR/Cas9 vector (lentiCRISPR v2), a gift from Feng Zhang (Addgene plasmid #52961; Cambridge, MA, USA). The lentiCRISPR v2 plasmids containing three M 3 -targeting sequences were mixed and transfected using Lipofectamine LTX Reagent. The transfected cells were maintained in the presence of 5 mg/mL puromycin to select for knockout cells. Once established, stable-knockout CR-M 3 cells were resuspended in high-glucose Dulbecco's modified Eagle's medium (DMEM) þ 10% dimethyl sulfoxide and frozen in liquid nitrogen for future use. 
Cell Culture and Transfection Protocols

CRE-Luc Luminescence Assay and Antagonist IC 50 Curves
Forty-eight hours after transfection, the cell medium was aspirated and replaced with various concentrations of antagonist diluted in FluoroBrite DMEM containing a fixed concentration of agonist (50 lL/well); treated cells were incubated for 4 hours at 378C under 5% CO 2 þ O 2 . The fixed agonist concentration (carbachol: 10 lM; or clonidine: 1 lM) was chosen, on the basis of preliminary concentrationresponse studies, to produce large but submaximal activation of normalized CRE-Luc luminescence (Luc N ). Submaximal concentrations (78%-90% activation) were used instead of 50% or 100% activation, so as to extend the dynamic range of measurable responses. The choice of antagonists for testing was based on availability and previously published reports of their ability to prevent FDM in the chick ( Table 1 ). All drug stock solutions (10 mM) were made using sterile distilled H 2 O, with the exception of QNB (5 mM) and himbacine (9 mM), which were dissolved in 100% and 90% methanol, respectively. The maximum concentration of methanol that did not cause cell death, as determined by Robust regression and Outlier removal (ROUT; GraphPad, La Jolla, CA, USA) statistical analysis, was 6%. Changes in intracellular cAMP were measured indirectly using the Dual-Glo Luciferase Assay System and protocol (Promega). Drug-treated cells and Dual-Glo assay reagents were equilibrated to room temperature, and then 50 lL Dual-Glo Luciferase Reagent was added to each sample well. The plate was incubated for 10 minutes at room temperature, with moderate shaking to ensure complete cell lysis. After incubation, CRE-Luc levels were measured using a Victor X4 Spectrophotometer (PerkinElmer, Waltham, MA, USA). Once CRE-Luc measurements were complete, 50 lL Dual-Glo Stopand-Glo Reagent was added to each of the sample wells, the 10minute incubation with shaking was repeated, and then the levels of RLuc (normalizing control) in the wells were measured in the same order, using the same spectrophotometer.
Data Analysis
Raw RLuc data were first subjected to outlier detection using ROUT analysis with a 1% false detection rate (GraphPad Prism v 6.07; La Jolla, CA, USA). Flagged data usually represented significant decreases in RLuc expression, due to cell death caused by high-concentration drug or methanol. There were no instances of significant cell death for any of the experiments involving testing at M 4 or cM 4 . At hADRA2A, cell death occurred at dicyclomine hydrochloride (DIC) (>500 lM), QNB (>300 lM, 6% methanol), oxyphenonium (OXY) (>3 mM), mepenzolate bromide (MEP) (>10 mM), and himbacine (HIM) (>500 lM). These data were removed along with their corresponding CRE-Luc values in the final analysis. Remaining CRE-Luc data were normalized to RLuc (CRE-Luc/RLuc ¼ Luc N ), and then either the fold-change Luc N (agonist treatment: [treated well À well without agonist] ‚ well without agonist) or the percent maximum response (antagonist treatment: [treated well ‚ well without antagonist] 3 100) was calculated. For graphing and IC 50 calculations, molar concentrations were graphed on the x-axis, transformed using the algorithm X ¼ Log(X), and then nonlinear regression analysis was performed. Graphical data are represented as curve-fitted linear regressions of the means of the transformed molar concentration values 6 SEM (GraphPad Prism, Version 6.07); n ¼ 3 or 4 experiments, performed in duplicate. Inhibitory constants (K i(CP) ) were estimated from these data by the method of Cheng and Prusoff (pK i(CP) ¼ IC 50 49, 50 where [A] ¼ agonist concentration used, and EC 50 was the agonist concentration required to elicit a 50% response, as determined by previous experiments using our assay system. Data are reported as either IC 50 (assay/system-dependent inhibitory potency), K i (absolute inhibitory potency), or EC 50 (assay/system-dependent excitatory potency) values. These values are all concentration-dependent; therefore, the smaller the value, the more effective the ligand. (Fig. 1 ). Inhibitory constants (K i ), estimated from these data by the method of Cheng and Prusoff, 49 were in good agreement with previously published affinity constant data for these ligands, either at human M 4 receptor or in mammalian tissues (Table 1) .
Chicken mAChR M 4
Carbachol treatment resulted in an increased induction of CRE-Luc-mediated luminescence (maximum 287-fold increase), similar to results reported previously, 44 with an EC 50 ¼ 2 lM; 10 lM was chosen as the fixed concentration, as it gave a large but submaximal activation of CRE-Luc induction (approximately 90% of maximum response). The behavior of antagonists at the cM 4 receptor did not mimic perfectly their behavior at human M 4 . Relative IC 50 values for cM 4 , in order from highest , and no myopia inhibition (filled symbols) according to previously published research, 14, 16, 19 and ranked in descending order from most to least potent in our receptor assay (IC 50 6 95% CI). MT3 (yellow) and atropine (blue) are indicated separately as they are the most researched anti-myopia mAChR antagonist in humans (atropine), and the most potent anti-myopia drug found to date in chicks (MT3). ATR, atropine sulfate; OXY, oxyphenonium bromide; PRZ, pirenzepine dihydrochloride; CI, confidence interval. , partial myopia inhibition (partially filled symbols), and no myopia inhibition (filled symbols) according to previously published research, 14, 16, 19 and ranked in descending order from most to least potent in our receptor assay (IC 50 6 95% CI). MT3 (yellow) and atropine (blue) are indicated separately as they are the most researched anti-myopia mAChR antagonist in humans (atropine), and the most potent anti-myopia drug found to date in chicks (MT3). ATR, atropine sulfate; OXY, oxyphenonium bromide; PRZ, pirenzepine dihydrochloride; CI, confidence interval.
to lowest potency, were QNB (310 pM) > oxyphenonium (560 pM) > atropine (710 pM) > mepenzolate (4 nM) > himbacine (6 nM) > dicyclomine (41 nM) > pirenzepine (49 nM) > tropicamide (245 nM) > MT3 (450 nM) (Fig. 2) . When converted by the Cheng-Prusoff correction, the IC 50 data for atropine, QNB, and pirenzepine are in good agreement with previously published K i values obtained by utilizing the same receptor clone 38, 51 (Table 1) . Although most antagonists acted with comparable relative inhibitory potencies at the cM 4 receptor and the human M 4 receptor, the K i for MT3 in blocking cM 4 was 56 times less potent (IC 50 ¼ 450 vs. 8 nM, respectively; P < 0.0001, unpaired t-test, 2-tailed). Thus, relative to all other mAChR antagonists tested, MT3 was the weakest antagonist at chick cM 4 .
Human a 2A -Adrenoceptor
Clonidine treatment of cells transiently transfected with hADRA2A resulted in increased CRE-Luc-mediated luminescence (maximum 26-fold increase), with an EC 50 ¼ 430 nM; 1 lM was chosen as the fixed concentration, as it gave a submaximal activation of CRE-Luc (approximately 78% of maximum response). Although increased cAMP synthesis is not the usual response to agonist treatment of G i -coupled receptors, this G s -coupling effect has been reported previously in CHO cells transfected with the hADRA2A receptor (also known as a2C10). 43 Relative IC 50 values for the mAChR antagonists at the hADRA2A receptor, ranked in order from highest to lowest potency, were MT3 (15 nM) > himbacine (17 lM) > atropine (45 lM) > oxyphenonium (463 lM) > pirenzepine (867 lM) > tropicamide (1.5 mM) > QNB (260 lM; maximum 82% inhibition) > mepenzolate (798 lM; maximum 68% inhibition) > > dicyclomine (no detectable activity) (Fig. 3) . The IC 50 for yohimbine, an a 2 -adrenergic antagonist, was 5 nM (calculated K i(CP) ¼ 2 nM). These data are in good agreement with previously published values for the affinity of MT3 (K i(CP) ¼ 5 nM) 29 ,52 and yohimbine (K i ¼ 400 pM-6 nM) [53] [54] [55] at the hADRA2A receptor (Table 2) . Thus, our data demonstrated unequivocally that myopia-inhibiting mAChR antagonists can bind to hADRA2A, although with affinities much lower than those with which they interact with mAChRs. The noteworthy exception was MT3, which bound to hADRA2A with an inhibitory potency (IC 50 ¼ 15 nM) comparable to that for its interaction with the human M 4 mAChR (IC 50 ¼ 8 nM).
Controls
Three different control experiments were conducted to verify that the changes in CRE-Luc, reflecting increases in intracellular cAMP, were due to activation of the transfected receptor and not stimulation of endogenous receptor signaling pathways. First, cells were transfected with the pcDNA 3.1(þ) plasmid only. There was no significant change in luminescence in response to carbachol or clonidine treatment (Supplementary Fig. S1 ). Second, the impacts of elevating intracellular calcium using a calcium ionophore (CI A23187), or activating protein kinase C with phorbol 12-myristate 13-acetate (PMA) were tested. CI A23187 treatment, resulting in an increase in intracellular Ca 2þ , could in principle cause activation of Ca 2þdependent cyclase and an increase in cellular cAMP, thereby mimicking the action of G q -coupled GPCRs ( Supplementary  Fig. S2 ). Alternatively, the protein kinase C (PKC) activator, PMA, could mimic the potential action of G q -protein-coupled receptors via phospholipase action, and raise both inositol triphosphate and diacylglycerol levels by activating cAMP response element binding protein (CREB)-thus causing increased luminescence without an increase in cellular cAMP ( Supplementary Fig. S2 ). Importantly, we observed no significant change in Luc N with treatment of either CI A23187 (1 lM) or PMA (10 lM), especially when compared to the response resulting from agonist treatment of transfected cells ( Supplementary Fig. S2 ).
DISCUSSION
The primary finding of our study is that the relative potencies of myopia-inhibiting mAChR antagonists to block the adrenergic hADRA2A receptor are correlated better with their ability to inhibit chick FDM than are the relative inhibitory potencies , partial myopia inhibition (partially filled symbols), and no myopia inhibition (filled symbols) according to previously published research, 14, 16, 19 and ranked in descending order from most to least potent in our receptor assay (IC 50 6 95% CI). MT3 (yellow) and atropine (blue) are indicated separately as they are the most researched anti-myopia mAChR antagonist in humans (atropine), and the most potent anti-myopia drug found to date in chicks (MT3). In this assay, dicyclomine is indicated by an open circle with a cross, because it had no activity at the hADRA2A receptor at the concentrations tested. YOH, yohimbine hydrochloride; ATR, atropine sulfate; OXY, oxyphenonium bromide; PRZ, pirenzepine dihydrochloride; CI, confidence interval.
of the same compounds to block the muscarinic M 4 /cM 4 receptors (Tables 1, 2 ; Fig. 4 ). The data correlating the relative abilities of the mAChR antagonists for myopia inhibition versus their relative K i values for blocking the chick and human mAChRs show MT3 as an obvious outlier (Figs. 4a, 4b , yellow circles). Yet, the same correlation plot paradigm shows that the relative K i of MT3 to block hADRA2A is tightly correlated, as are the K i values of the other mAChR antagonists, with the ability to attenuate chick FDM (Fig. 4c, yellow circle) . These findings support the hypothesis that myopia inhibition by highconcentration mAChR antagonists may be mediated by receptors other than mAChR M 4 /cM 4 , and our data point to members of the a-adrenoceptor family as possible alternatives. A secondary finding is that, although the relative inhibitory potencies of most myopia-inhibiting mAChR antagonists for blocking the chick cM 4 compared with the human M 4 receptors are in good agreement, MT3 is an anomaly; it has markedly reduced K i for the chick cM 4 receptor compared with the human M 4 receptor. This result is likely due to differences in the ligand-binding sites on the two receptors.
Distribution of Drugs Within Ocular Tissues After Different Delivery Methods
A question to ask about the use of atropine for myopia inhibition (in humans and animals) is, Does the high concentration of antagonist, as administered, reflect its concentration at the site of action in the eye? Currently, the site of action for atropine-mediated myopia inhibition is unknown, but best guesses identify the retina, choroid, and/ or sclera. 56 In chicks, intravitreal injection is the usual method of delivery, and concentrations of 1 to 100 mM have been used for mAChR antagonist-mediated inhibition of FDM 16, 57, 58 (Table  1) . Unfortunately, no studies exist on the ocular distribution of atropine after intravitreal injection into chick eyes; but one study has investigated the ocular distribution, in chicks, of a single dose of intravitreally injected radioactively labeled pirenzepine. 59 At 1 hour after injection, reported concentrations (percentage of the original injected amount) were 6% in the retina, 1.5% in the choroid, and 2.5% in the sclera. 59 Based on these data, and considering that 100 mM was used to achieve full myopia inhibition in the chick, 16 estimated concentrations for ocular tissues would be retina ¼ 6 mM, choroid ¼ 1.5 mM, and sclera ¼ 2.5 mM. These estimated concentrations greatly exceed those that would be expected to have mAChR-only effects, and fall within the range of concentrations that would enable pirenzepine to block the hADRA2A receptor under in vitro conditions, as calculated by our assay (K i(CP) ¼ 250 lM; Table 2 ). In humans, atropine for myopia inhibition is delivered in the form of daily eye drops (0.01%-1%). Under experimental conditions, delivery of a single dose of 2% [ 3 H]-atropine to the conjunctival sac of albino rabbits resulted in a distribution of the original concentration of 0.09% in the sclera, 0.05% in the choroid, and 0.008% in the retina, 1 hour after instillation 60 ; similar results (retina: 0.01%; choroid and sclera 0.38%) were seen 30 minutes after topical application of [C 14 ]-atropine. 61 Therefore, the concentrations of atropine in the eye after a single topical application of 0.01% to 1% (0.13-13 lM in the sclera, 0.07-7 lM in the choroid, and 0.01-1.1 lM in the retina, extrapolated from single-dose studies in albino rabbit 60, 61 ) are within the range of what we have found to be the IC 50 for atropine's ability to block the hADRA2A in in vitro cell culture preparations (our value ¼ 45 lM; value reported by others ¼ 1-10 lM). 30, 31 The ocular distribution of atropine after multiple topical doses has not been determined, but studies monitoring the accumulation of atropine in humans have shown that atropine buildup can occur. Serum levels of atropine were undetectable after a single inhalation dose of 12 to 25 ng/lL atropine sulfate, but were raised to 1.13 to 5.23 ng/lL when treatment was administered every 4 to 6 hours over a period of 48 hours. 62 Pigmented tissues (RPE, iris, ciliary body, choroid, and retina) are especially apt at retaining atropine, which may lead to an initially weaker but significantly prolonged effect. 63, 64 It is possible, then, that topical Non-ADRA2A-specific receptors/tissues: chick pineal, 128 chick cortex, 130 rabbit pulmonary artery. 31 K i /ED 50 Study and IC 50 Study data are the data determined by our binding assay, K i(CP) data are calculated from the IC 50 values in our assay by the method of Cheng and Prusoff, 49 and K i /ED 50 Literature and K i Literature data are data from previously published studies. Maximum inhibition achieved was 100%, unless indicated otherwise by percent values in parentheses beside the reported IC 50 . YOH, yohimbine hydrochloride; Clon, clonidine hydrochloride; ATR, atropine sulfate; OXY, oxyphenonium bromide; PRZ, pirenzepine dihydrochloride; Est.
[Vit], estimated vitreal concentrations, assuming uniform dilution in total vitreal volume, required for myopia inhibition in the chick; N/A, not available.
* Human or mammalian mAChR M 4 receptor or tissue. † Avian mAChR M 4 receptor or tissue. application of 0.01% atropine daily for long periods (up to 2 years) could result in ocular concentrations much higher than those seen after a single dose, with intracellular organelles such as melanin granules acting as reservoirs for slow release of the drug and possibly providing local concentrations that would be sufficient to interact with non-mAChRs. Pirenzepine has also been tested for the treatment of childhood myopia, with twice-daily applications of concentrations up to 2%; but the results did not support superiority of clinical efficacy of pirenzepine treatment over atropine treatment, [65] [66] [67] [68] and further studies have seemingly been abandoned. 69 Ocular distribution of a single dose of topically applied [ 3 H]-pirenzepine (2%) has also been tested in the rabbit eye; concentrations in the ocular tissues 1 hour after administration were roughly half those calculated for atropine (retina: 0.004%, choroid: 0.021%, sclera: 0.052%)-possibly because atropine, being more lipophilic, is better at penetrating the ocular tissues and is lost less rapidly than pirenzepine. 60 The estimated concentrations of pirenzepine delivered to ocular tissues should be sufficient to activate all mammalian mAChR subtypes fully, 70 but are expected to fall below the concentration required to achieve a significant blockade of hADRA2A signaling (retina: 2 lM, choroid: 12 lM, sclera: 30 lM) as calculated by our assay (K i(cp) ¼ 250 lM, Table 2 ).
mAChR Antagonists at M 4 , cM 4 
, and hADRA2A Receptors: Correlations With Myopia Inhibition
The relative inhibitory potencies of myopia-inhibiting mAChR antagonists at the hADRA2A receptor, but not at the chick cM 4 and human M 4 mAChRs, are well correlated with their reported ability to inhibit chick FDM 14, 16, 19 (Fig. 4) . We have confirmed previous reports of high-affinity binding of MT3 29, 52 (K i(CP) ¼ 5 nM) to hADRA2A, and demonstrated that atropine and himbacine can also bind to this receptor, albeit with potencies much lower than their relative K i values for blocking the mAChRs. All other mAChR antagonists tested had very low potency for blocking hADRA2A, but 100% inhibition of clonidine-mediated effects was achieved with oxyphenonium, tropicamide, and pirenzepine-drugs that were reported to inhibit myopia fully in the chick when used at high concentrations. The maximum inhibitory effects achieved by QNB (partial myopia inhibition in chick) and mepenzolate (no myopia inhibition in chick) were 82% and 68%, respectively, and dicyclomine (no myopia inhibition in chick) had no discernable effect at the concentrations tested. At the human and chick M 4 /cM 4 receptors, atropine, QNB, mepenzolate, and dicyclomine are all comparably potent inhibitors, with K i values in the nanomolar range; yet atropine is the only one of these that can inhibit chick FDM. 16 Most interesting is the behavior of MT3 at M 4 /cM 4 . It is the most effective drug found to date for mitigating chick FDM, 14, 15 and we confirmed its high potency for the human M 4 receptor. However, we found it to be the least potent of all drugs tested at the chick cM 4 receptor. This disconnect, between the potency of MT3 at cM 4 and its effectiveness against chick FDM, supports our hypothesis that myopia inhibition is not mediated by the M 4 / cM 4 receptor.
Difference in Binding of MT3 at M 4 Versus cM 4
When attempting to assign functional consequences to treatment with a particular ligand, it is important to consider the mechanism of binding of that ligand to its target receptor. Generally, orthosteric binding sites, where the transmitters or primary signaling molecules bind, are highly conserved (100%) between receptors of the same class and between species. 71 ''Selective'' modulatory ligands such as MT3, however, will bind to receptor amino acid residues that are less conserved, usually outside the orthosteric pocket, in the extracellular loops (EL2 and EL3) of the target GPCR. 39 In such instances, substitution of even a single amino acid can have a significant impact on ligand-receptor binding characteristics. 39, 40 Thus, while decreased conservation of receptor sequences in the extracellular loops aids in selectivity of a ligand for a certain receptor subtype, the increasingly stringent requirements for binding can also result in loss of activity at the same receptor subtype in other species. This finding is what we observed in our assay: MT3 bound poorly to cM 4 compared to M 4 . Chicken and human M 4 share only a 71.4% to 72.7% sequence identity in EL3 and EL2, respectively ( Supplementary Fig. S3 ). Therefore, it is likely that the decreased activity of MT3 at cM 4 is caused by amino acid differences in its EL2 and EL3 sequences, compared to those of M 4 . All other drugs tested in our assay did not differ significantly in their binding behavior at M 4 versus cM 4 . This result was expected; these ligands are known to be orthosteric inhibitors of ACh at mAChRs, and the reported orthosteric binding site of the mAChR M 4 /cM 4 receptors is 100% conserved between human and chick 71 ( Supplementary Fig. S3 ).
Ocular a-Adrenoceptors and Possible Mechanism of Action
Sympathetic innervation in the vertebrate eye services structures such as the dilator pupillae, the ciliary muscle and epithelium, and ocular blood vessels within and outside the choroid. 72 Alpha 2 -adrenoceptors are best known as autoreceptors, but they can also act as heteroreceptors. 41, 73 Alpha 2adrenoceptors that act as autoreceptors are located on presynaptic adrenergic neurons; they are activated by epinephrine/norepinephrine and inhibit the release of their own neurotransmitters. Alpha 2 -adrenoceptors that act as heteroreceptors are located presynaptically on nonadrenergic neurons, and there is evidence that a 2 -adrenoceptors can modulate the release of neurotransmitters such as GABA, dopamine, and serotonin in the rat brain and retina. [74] [75] [76] [77] [78] [79] Interestingly, both GABA and dopamine have been implicated in the regulation of eye growth. [80] [81] [82] [83] [84] [85] [86] [87] [88] In the rat retina, the epinephrine-synthesizing enzyme phenylethanolamine N-methyltransferase (PNMT) has been localized to amacrine cell populations 89 and retinal epinephrine levels have been reported to rise upon light exposure 90, 91 ; but there is no further evidence for a role of epinephrine or norepinephrine in retinal visual processing of any vertebrate species examined. In spite of this, a-adrenoceptors are present on retinal neurons. In rat retina, human, and primate tissue, ADRA2A immunoreactivity has been localized to the nonpigmented ciliary epithelium, cornea and conjunctiva, and retinal ganglion cells and amacrine cells. 92 In 4 . Correlations between rank order inhibitory potency (x-axis) and rank order inhibition of axial elongation in chicks with experimentally induced FDM (y-axis) for mAChR antagonists at M 4 (a), cM 4 (b), and hADRA2A (c). Rank orders for both parameters are 1 ¼ least potent (pIC 50 ) or effective (% axial length inhibition) and 9 ¼ most potent (pIC 50 ) or effective (% axial length inhibition). A line of unity (slope ¼ 1) has been superimposed upon the graphs for visual reference. Inhibitory potencies of mAChR antagonists, and their abilities to inhibit FDM in the chick, correlate significantly for hADRA2A only (r ¼ 0.87, P < 0.01; Spearman's ranked correlation). Atropine and MT3 are shown in color (atropine ¼ blue, MT3 ¼ yellow). Full inhibition of axial elongation (open/colored symbols), partial inhibition of axial elongation (partially filled symbols), and inhibition of axial elongation (filled symbols) according to previously published research in the chick. 14, 16, 19 a transgenic mouse expressing an N-terminal hemagglutinin epitope (HA)-tagged a 2A -receptor, driven by the endogenous ADRA2A gene locus, ADRA2A gene expression was localized to horizontal cells, inner nuclear layer, inner plexiform layer, and the retinal ganglion cell layer (Rao SS, et al. IOVS 2011;52:AR-VO E-Abstract 2059). In chick, immunoreactive ADRA2A has been localized to retinal Müller cells, amacrine cells, and ganglion cells (Costa GV, et al. IOVS 2012;53:ARVO E-Abstract 6545). 93 Ocular a 2 -adrenoceptors are implicated in the pathogenesis of glaucoma, and a 2 -adrenoceptor agonists, such as brimonidine and apraclonidine, are clinically approved for management of intraocular pressure (IOP). The prevalence of glaucoma is said to be correlated with the prevalence of myopia, 94, 95 and new evidence suggests that these a 2adrenoceptor agonists can inhibit myopia in chicks (Carr BJ, Stell WK. IOVS 2016;57:ARVO E-Abstract 4738) and guinea pigs. 43 It is still unknown which neural circuits or receptors might mediate these effects, but Liu et al. 43 suggested that attenuation of IOP is responsible for inhibition of myopia in guinea pigs. A direct mechanical influence of IOP (within the physiological range) on axial elongation, as hypothesized by Pruett 96 and others, [97] [98] [99] does not seem likely, however. Human clinical studies have found no relationship, [100] [101] [102] [103] an increase in IOP after but not preceding the onset of myopia, 99, 104 or a small decrease in IOP before onset of childhood myopia 103 ; animal studies have produced equally equivocal results. 97, 105 A possible reason for this could be measurement bias induced by utilizing indentation or applanation tonometry, which calculates IOP from the amount of pressure required to flatten an area of the cornea. The accuracy of tonometry is dependent on factors such as corneal thickness 106 and scleral compliance, 107, 108 and increased scleral compliance (scleral creep) has been observed in humans with pathologic myopia 109 and mammals with experimentally induced myopia. 110, 111 Thus, if the sclera is more compliant than normal, it may lead to a mistaken measurement bias toward lower IOP. In contrast, a 2 -adrenoceptor agonists also were reported to effectively inhibit FDM in chicks (Carr BJ, Stell WK. IOVS 2016;57:ARVO E-Abstract 4738), in which there is no increase in scleral compliance in response to myopiagenic stimuli 111 ; IOP measurements were not recorded in that study, however, so we cannot exclude a role completely. The relationship between the actions and receptor targets of the compounds we studied and their impact on IOP and myopia remains an interesting topic for future work. Notwithstanding the possible role of IOP in myopia, our work establishes clearly that action of atropine via the mAChR M 4 receptor is highly unlikely to be a factor. Alpha 2 -adrenoceptor agonism in the retina can also result in the upregulation of neuroprotective agents and mechanisms, such as an increase in basic fibroblast growth factor (bFGF) in rat photoreceptors 112, 113 or activation of the extracellular signal-regulated kinase signaling pathway in chick Müller cells. 93 Interestingly, both bFGF and extracellular signalregulated kinase signaling have been implicated in protection against chick FDM 114, 115 and guinea pig lens-induced myopia. 42, 116, 117 Finally, brimonidine might be involved in the regulation of nitric oxide synthase in retinal arterioles, where it may activate endothelial nitric oxide synthase (eNOS), resulting in vasodilation, as reported in pigs. 118 It is important to note that although there are no intraretinal blood vessels in the chick retina, it is served by blood vessels in the choroid and an intravitreal structure called the pecten. Whether a 2adrenoceptor ligands can also modulate NOS (neuronal NOS, eNOS, or inducible NOS) activity or expression in retinal neurons is worth investigating further, since synthesis and release of nitric oxide are necessary for myopia inhibition by atropine, and have been associated strongly with reduction of eye growth. 57 
Caveats and Considerations
There are some discrepancies in the ability of mamba toxins to inhibit myopia in different animal models. Although MT3 inhibits FDM effectively in chicks 14 and tree shrews, 17 it seems to be ineffective at inhibiting the axial elongation induced by lens-induced myopia (LIM) in the same animals. 15, 17 Conversely, MT7, a mamba toxin subtype that is highly selective for mAChR M 1 and is not known to act at any other receptor, 28, 29 inhibits LIM, but not the axial elongation induced by FDM, in the tree shrew. 17 MT7 has no effect in the chick, 119 which is expected because chicks do not possess the M 1 subtype. Pirenzepine, however, is effective at inhibiting chick FDM, possibly due to binding to the cM 2 receptor, which MT7 does not recognize, or to off-target binding at a 2 -adrenoceptors as evidenced by our work. These differences in treatment effectiveness of mamba toxins are in line with evidence suggesting that the circuits involved in LIM and FDM are in some ways different, [120] [121] [122] and thatwhatever the mechanism affected by atropine (and other myopia-inhibiting mAChR antagonists) is-the results of our study may be unique to the circuitry of FDM, and not LIM.
Although we have shown that some mAChR antagonists will bind hADRA2A at high concentrations-comparable to those found to be effective against chick FDM-we have not ruled out other a-adrenoceptor subtypes, non-M 4 muscarinic subtypes (i.e., mAChR M 1 /cM 2 ), or non-mAChR/nonadrenergic receptor targets. The high concentrations of these drugs required to inhibit FDM in the chick model impede our ability to identify any single receptor as the key target for the impact of any compound on myopia, because of the distinct possibility of many unidentified off-target receptor-mediated effects. 21 Furthermore, because of technical issues we could not overcome, we were unable to express a functional chick ADRA2A receptor in our HEK cell expression system, which would have enabled us to compare the ''nonspecific'' affinities of mAChR antagonists directly for the chick versus human a 2Aadrenoceptors. What can be concluded with confidence from our data, however, is that M 4 /cM 4 cannot be seen as the unique or even the leading receptor candidate for mediating the inhibition of FDM by atropine (and other mAChR antagonists) in the chick bioassay.
Summary
Our data provide new information about the relative potencies of muscarinic antagonists at the human and chick mAChR M 4 / cM 4 receptors and the human a 2A -adrenoceptor. This is the first study to characterize the inhibitory action of oxyphenonium, mepenzolate, MT3, dicyclomine, and tropicamide explicitly at chicken cM 4 , and the first to test specifically and report in detail, the potential ''off-target'' actions of multiple mAChR antagonists at hADRA2A. Consequently, these data provide a concentration range over which these drugs should be expected to act in a mAChR-specific manner, and a concentration range at which they can be predicted to have ''off-target'' effects at hADRA2A and possibly other receptors. The focus of thinking about the anti-myopia action of atropine as muscarinic, combined with the lack of knowledge of the mechanism of atropine's therapeutic actions (in the setting of either human or chick myopia), is a deterrent to the discovery of more effective anti-myopia agents with fewer side effects. The data presented here make a compelling case for continued investigation into non-mAChR targets for atropine-mediated myopia inhibition, with a-adrenoceptors being provocative candidates for novel therapeutic interventions.
